17.64
price down icon9.70%   -1.895
pre-market  Vorhandelsmarkt:  17.62   -0.015   -0.09%
loading
Schlusskurs vom Vortag:
$19.53
Offen:
$19.45
24-Stunden-Volumen:
4.36M
Relative Volume:
2.69
Marktkapitalisierung:
$1.76B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-9.7431
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
-24.05%
1M Leistung:
-33.05%
6M Leistung:
-24.67%
1J Leistung:
-46.00%
1-Tages-Spanne:
Value
$17.55
$19.45
1-Wochen-Bereich:
Value
$17.55
$23.18
52-Wochen-Spanne:
Value
$17.55
$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Firmenname
Beam Therapeutics Inc
Name
Telefon
857-327-8775
Name
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Mitarbeiter
483
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
BEAM's Discussions on Twitter

Vergleichen Sie BEAM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BEAM
Beam Therapeutics Inc
17.64 1.76B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-28 Hochstufung BofA Securities Neutral → Buy
2025-03-10 Hochstufung Scotiabank Sector Perform → Sector Outperform
2025-01-29 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-11-06 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-07-23 Eingeleitet H.C. Wainwright Buy
2024-01-29 Hochstufung JP Morgan Neutral → Overweight
2023-12-15 Herabstufung BofA Securities Buy → Neutral
2023-12-08 Herabstufung Jefferies Buy → Hold
2023-10-20 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-10-20 Herabstufung Leerink Partners Outperform → Market Perform
2023-03-21 Eingeleitet Bernstein Mkt Perform
2023-02-01 Eingeleitet Cantor Fitzgerald Overweight
2022-12-20 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-12-13 Eingeleitet Citigroup Buy
2022-06-17 Eingeleitet BMO Capital Markets Market Perform
2022-04-28 Eingeleitet Credit Suisse Neutral
2022-01-05 Eingeleitet Guggenheim Buy
2021-10-19 Eingeleitet SVB Leerink Outperform
2021-09-24 Fortgesetzt Stifel Buy
2021-09-10 Eingeleitet BofA Securities Buy
2021-05-11 Eingeleitet Redburn Buy
2021-05-04 Eingeleitet RBC Capital Mkts Sector Perform
2021-03-01 Herabstufung Barclays Overweight → Equal Weight
2021-02-16 Eingeleitet Wells Fargo Overweight
2021-01-29 Herabstufung JP Morgan Overweight → Neutral
2021-01-06 Eingeleitet Stifel Hold
2020-08-05 Eingeleitet William Blair Outperform
2020-03-02 Eingeleitet Barclays Overweight
2020-03-02 Eingeleitet JP Morgan Overweight
2020-03-02 Eingeleitet Jefferies Buy
2020-03-02 Eingeleitet Wedbush Outperform
Alle ansehen

Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten

pulisher
Apr 01, 2025

Beam Therapeutics Becomes Oversold - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

8 Best Gene-Editing Stocks to Buy - Insider Monkey

Mar 31, 2025
pulisher
Mar 31, 2025

Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN

Mar 31, 2025
pulisher
Mar 28, 2025

Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

B of A Securities Upgrades Beam Therapeutics (BMV:BEAM) - Nasdaq

Mar 28, 2025
pulisher
Mar 28, 2025

Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

BofA raises Beam Therapeutics stock rating to Buy, sets $42 target - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

BofA raises Beam Therapeutics stock rating to Buy, sets $42 target By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

BofA Securities Upgrades Beam Therapeutics to Buy From Neutral - Marketscreener.com

Mar 28, 2025
pulisher
Mar 27, 2025

FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Tr - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration - The Manila Times

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) By The United States (U.S.) Food And Drug Administration - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: FDA Green Lights Beam's Revolutionary Gene Editing Drug for Rare Disease - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 27, 2025
pulisher
Mar 25, 2025

Beam Therapeutics stock holds firm with $37 target at Bernstein By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Cathie Wood’s ARK focuses on Beam Therapeutics, Intuitive Machines stock - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Beam Therapeutics stock holds firm with $37 target at Bernstein - Investing.com

Mar 25, 2025
pulisher
Mar 22, 2025

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga

Mar 22, 2025
pulisher
Mar 21, 2025

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) - The Globe and Mail

Mar 21, 2025
pulisher
Mar 19, 2025

Beam Therapeutics’ $500 Million Common Stock Offering - Global Legal Chronicle

Mar 19, 2025
pulisher
Mar 19, 2025

Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily

Mar 19, 2025
pulisher
Mar 18, 2025

Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive

Mar 18, 2025
pulisher
Mar 18, 2025

3 Gene Therapy Stocks to Watch Amid Industry Turmoil - Schaeffers Research

Mar 18, 2025
pulisher
Mar 17, 2025

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study - MSN

Mar 17, 2025
pulisher
Mar 16, 2025

Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? - Insider Monkey

Mar 16, 2025
pulisher
Mar 16, 2025

BEAM Down Despite Positive Initial Data From Genetic Disorder Study - MSN

Mar 16, 2025
pulisher
Mar 14, 2025

Wedbush Research Analysts Raise Earnings Estimates for BEAM - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Citi lifts Beam Therapeutics stock price target to $64 - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Citi lifts Beam Therapeutics stock price target to $64 By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial - CRISPR Medicine News

Mar 12, 2025

Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Kapitalisierung:     |  Volumen (24h):